Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ – Get Free Report) saw a large decline in short interest in September. As of September 15th, there was short interest totaling 84,256 shares, a decline of 69.1% from the August 31st total of 272,812 shares. Based on an average daily trading volume, of 172,085 shares, the days-to-cover ratio is currently 0.5 days. Currently, 1.3% of the shares of the stock are sold short.
Analysts Set New Price Targets
A number of equities research analysts have issued reports on CELZ shares. Weiss Ratings lowered Creative Medical Technology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday. Roth Capital reiterated a “buy” rating on shares of Creative Medical Technology in a research report on Thursday, August 20th. Finally, Wall Street Zen raised Creative Medical Technology from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Creative Medical Technology has a consensus rating of “Hold”.
Get Our Latest Research Report on CELZ
Creative Medical Technology Stock Performance
Creative Medical Technology (NASDAQ:CELZ – Get Free Report) last issued its earnings results on Friday, August 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.02). Sell-side analysts predict that Creative Medical Technology will post -1.18 earnings per share for the current fiscal year.
Creative Medical Technology Company Profile
Creative Medical Technology Holdings, Inc is a biotechnology company focused on developing regenerative medicine and cell-based therapies. The company’s research programs are aimed at conditions involving inflammation, autoimmune dysfunction, tissue damage and sexual health.
Its pipeline has included ImmCelz, an immunomodulatory cell-therapy platform, as well as CaverStem for erectile dysfunction, FemCelz for female sexual health, KneeCelz for knee-related conditions and StemSpine for spinal disorders.
See Also
- Five stocks we like better than Creative Medical Technology
- Data Centers Got the AI Hype—But Office REITs May Get the Rent Hikes
- 2 Cybersecurity Stocks Breaking Out as AI Continues to Be a Tailwind
- 3 More AI Infrastructure Plays Beyond the Big Names
- CAVA Stock Slips: Sector Fear or Valuation Reality?
Receive News & Ratings for Creative Medical Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Creative Medical Technology and related companies with MarketBeat.com's FREE daily email newsletter.
